Patient characteristics are consistent with other DLB studies -PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, ...

presented participant baseline characteristics in the Phase 2 ‘SHIMMER’ study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17th Annual Clinical ...

For more information, or to sign-up to volunteer, go to https://www.concernedforthehungry.org. Fall-La-Palooza event aims to ...

CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from ...

There are already millions of Dementia Friends in England and Wales! Students who complete the activities will be awarded a badge and a poster for their school. Available for Key Stage 1, 2, 3 and 4.

presented participant baseline characteristics in the Phase 2 ‘SHIMMER’ study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17 th Annual Clinical Tr ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

"Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research." This prestigious workshop, sponsored by the NIA and the National Institute of Neurological Disorders and Stroke ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

AbbVie has an exclusive option to globally develop and commercialize AL002. Alector will deliver a data package resulting ...

Ms. Ricciardi concluded: "In addition to the substantial progress we have made with CT1812 in Alzheimer's disease, we expect to report top-line results from our Phase 2 SHIMMER study in ...